Skip to main content
Burak Ozpineci is a globally recognized leader in power electronics research. He was named an ORNL Corporate Fellow in fall 2021. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

Burak Ozpineci started out at ORNL working on a novel project: introducing silicon carbide into power electronics for more efficient electric vehicles. Twenty years later, the car he drives contains those same components.

AIST Conference

As the United States transitions to clean energy, the country has an ambitious goal: cut carbon dioxide emissions in half by the year 2030, if not before. One of the solutions to help meet this challenge is found at ORNL as part of the Better Plants Program.

Researchers studying secondary metabolites in the fungus Aspergillus flavus, pictured, found unique mixes of metabolites corresponding to genetically distinct populations. The finding suggests local environmental conditions play a key role in secondary metabolite production, influencing the discovery of drugs and other useful compounds. Credit: Tomás Allen Rush/ORNL, U.S. Dept. of Energy.

Scientists at ORNL and the University of Wisconsin–Madison have discovered that genetically distinct populations within the same species of fungi can produce unique mixes of secondary metabolites, which are organic compounds with applications in

An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus. Credit: Michelle Lehman/ORNL, U.S. Dept. of Energy

An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.

L-R: ORNL’s Omer Onar and Veda Galigekere with the dynamic wireless charging test bed at ORNL’s Grid Research Integration and Deployment Center. Credit: Carlos Jones, ORNL/U.S. Dept. of Energy

Consumer buy-in is key to the future of a decarbonized transportation sector in which electric vehicles largely replace today’s conventionally fueled cars and trucks.

ORNL’s Sergei Kalinin and Rama Vasudevan (foreground) use scanning probe microscopy to study bulk ferroelectricity and surface electrochemistry -- and generate a lot of data. Credit: Jason Richards/ORNL, U.S. Dept. of Energy

At the Department of Energy’s Oak Ridge National Laboratory, scientists use artificial intelligence, or AI, to accelerate the discovery and development of materials for energy and information technologies.

Belinda Akpa applies her diverse expertise and high-performance computing to accelerate the drug discovery process and increase the chances of success when candidate molecules go to clinical trials. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.

Heavy-duty vehicles contribute 23% of transportation emissions of greenhouse gases and account for almost one-quarter of the fuel consumed annually in the U.S. Credit: Chris Bair/Unsplash

Through a consortium of Department of Energy national laboratories, ORNL scientists are applying their expertise to provide solutions that enable the commercialization of emission-free hydrogen fuel cell technology for heavy-duty

Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.

Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.

ATOM logo

The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.